Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Gains from Sales and Divestitures (2023 - 2025)

Maxcyte (MXCT) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $609460.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 45.71% to $609460.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $609460.0 through Dec 2025, up 45.71% year-over-year, with the annual reading at $609460.0 for FY2025, 45.71% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $609460.0 at Maxcyte, up from $418260.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $609460.0 in Q4 2025, with the low at $288550.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 3 years is $438756.7, with a median of $418260.0 recorded in 2024.
  • The sharpest move saw Gains from Sales and Divestitures skyrocketed 44.95% in 2024, then skyrocketed 45.71% in 2025.
  • Over 3 years, Gains from Sales and Divestitures stood at $288550.0 in 2023, then surged by 44.95% to $418260.0 in 2024, then skyrocketed by 45.71% to $609460.0 in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $609460.0, $418260.0, and $288550.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.